US Patent 10253083 Therapeutic uses of modified relaxin polypeptides
Patent 10253083 was granted and assigned to Ambrx on April, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+425 characters)
Article
Patent abstract
Therapeutic uses of modified relaxin polypeptides for the treatment of cardiovascular disease, treatment of heart failure, and decreasing fibrotic disorders are provided. Exemplary embodiments provide for the use of relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol.
Edits on 18 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 28 Jul, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 5 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
102530830
Date of Patent
April 9, 2019
0Patent Application Number
153863470
Date Filed
December 21, 2016
0Patent Citations Received
Patent Primary Examiner
Edits on 4 Apr, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 24 Mar, 2023
Golden AI
Infobox
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
102530830
Date of Patent
April 9, 2019
0Patent Application Number
153863470
Date Filed
December 21, 2016
0Patent Citations Received
Patent Primary Examiner
Edits on 26 Sep, 2022
Golden AI
Infobox
Patent Citations Received
Golden AI
Infobox
Edits on 24 Sep, 2022
Golden AI
Infobox
Edits on 19 Sep, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 22 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 19 May, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 25 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10253083 Therapeutic uses of modified relaxin polypeptides
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10253083
Date of patent
April 9, 2019
Patent application number
15386347
Date Filed
December 21, 2016
Patent primary examiner
Find more entities like US Patent 10253083 Therapeutic uses of modified relaxin polypeptides
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
